Panel Leans Toward Valsartan MDL, But Grapples With Scope

Law360 (January 31, 2019, 11:26 PM EST) -- The Judicial Panel on Multidistrict Litigation indicated Thursday that it will centralize cases arising from recent recalls of the generic blood pressure drug Valsartan due to contamination by known carcinogens, but numerous questions remain about the appropriate scope and eventual landing spot.

In addition to considering a possible venue for consolidation, the seven-judge panel, which held oral arguments in Miami, must also decide whether common issues exist to consolidate claims regarding products manufactured by different companies in China and India, items involving different contaminants, and whether it would be most efficient to roll in personal injury cases along with consumer fraud...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS